News that GlaxoSmithKline is facing difficulties enrolling enough patients in a clinical trial for its diabetes drug Avandia should come as no surprise to readers of my book, Get to Market Now. The pre-informed patient is beginning to impact drug development and postmarket clinical trials… Continue reading at ComplianceZen.com →
From the Blog
Lowering Liability Risks with Supplier Qualification
FDA Compliance Training – Free Consulting?
From the NIH – Biotechnology Landscape 2020
FDA Forecast for 2012
From the PCP Council Science Symposium
Client Success Stories
“John Avellanet provides excellent advice that is both compliant and reasonable. He also works within the constraints of a company’s business realities when providing advice. This has helped integrate the controls into our company much faster and for a lot less; with our small staff and low budget, this has been extremely helpful. I would recommend Cerulean for small to mid-size firms that need to be in regulatory compliance with the FDA and want to get to market (or partnership) quickly.”
- Michael Weber, Director of Quality, Williamsburg, Virginia
